公司資料

Biogen 股價、新聞與催化劑

股票代碼:
BIIB
交易所:
NASDAQ
產業:
Biopharma
所在地:
United States

股票表現

247.13 USD (-1.70%)

收盤價

最後更新: 2026年11月19日

27.9B USD

市值

股價為何變動

截至 2026年11月19日,BIIB 下跌 1.70%,收於 $247.13。目前新聞監測窗口內未發現新的同公司新聞。

公司概覽

業務概覽

Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.

所在地與產業分類

Biogen is headquartered in the United States and listed on NASDAQ. It sits in large-cap biotechnology with a neuroscience identity.

商業模式特徵

The company generates value through product sales, lifecycle management, and ongoing R&D in difficult CNS and rare-disease areas. Investors watch launch execution, pipeline progress, and franchise durability.

生技產業定位

Biogen occupies one of the most important large-cap neuroscience positions in biotech. It is far less binary than a small-cap name, but major pipeline and label events still matter a lot.

未來催化劑

  • Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.

近期新聞

新聞標題由機器翻譯,詳情為英文原文。

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

相似股票

商業成熟度、治療領域或催化劑模式相近的同業公司。